Trial · NCT03536884
Participant flow144
How many started, completed or left each group, period by period.
1 to 20 of 144
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | ITP: Bimekizumab (BKZ) 320 Milligrams (mg) Q4W | 373 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | ITP: Secukinumab 300 mg Q4W | 370 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | MTP: BKZ 320 mg Q4W/Q8W | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | MTP: BKZ 320 mg Q4W/Q4W | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | MTP: Secukinumab 300 mg Q4W/Q4W | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | OLE Period: BKZ Week 0-48/BKZ Q8W 320 mg | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | OLE Period: BKZ Week 0-48/ BKZ Q4W 320 mg | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | OLE Period: Secukinumab Week 0-48/ BKZ Q8W 320 mg | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | OLE Period: Secukinumab Week 0-48/ BKZ Q4W 320 mg | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | OLE2 Period - Group A: BKZ 320 mg Q8W | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | OLE2 Period - Group B: BKZ 320 mg Q8W | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | STARTED | OLE2 Period -Group B: BKZ 320 mg Q4W/Q8W | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | COMPLETED | ITP: Bimekizumab (BKZ) 320 Milligrams (mg) Q4W | 362 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | COMPLETED | ITP: Secukinumab 300 mg Q4W | 354 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | COMPLETED | MTP: BKZ 320 mg Q4W/Q8W | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | COMPLETED | MTP: BKZ 320 mg Q4W/Q4W | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | COMPLETED | MTP: Secukinumab 300 mg Q4W/Q4W | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | COMPLETED | OLE Period: BKZ Week 0-48/BKZ Q8W 320 mg | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | COMPLETED | OLE Period: BKZ Week 0-48/ BKZ Q4W 320 mg | 0 | |
| Double-Blind (DB) Period: ITP Wk 0-16 | COMPLETED | OLE Period: Secukinumab Week 0-48/ BKZ Q8W 320 mg | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03536884/flow